Fundraising FoxSan Francisco · Seed–Late Stage · 17 people tracked
Also known as ECOR1 CAPITAL, LLC
Find your way into EcoR1 Capital
Sign up to see every warm intro you have to EcoR1 Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the EcoR1 Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
EcoR1 Capital takes a holistic yet highly targeted approach to identifying innovative therapeutics capable of meaningfully improving patient lives. The firm positions itself as patient-driven, investing with conviction in companies believed to have the greatest potential to benefit patients. It emphasizes fluency in both the scientific and strategic dimensions of biosciences, enabling it to act as a thought partner to its portfolio companies. Its evaluation framework is multi-dimensional, beginning with an assessment of management quality, scientific strength, and rational financing strategies before conducting deeper diligence.
Source: firm website, verified Sep 29, 2026.
Team · 17 people
from the firm's website & public directories
What they invest in
from 67 of 77 portfolio companiesBiotech ×60Healthtech ×26Medical Devices ×22AI & Machine Learning ×12Deep Tech ×12Digital Health ×12Enterprise Software ×2Gaming ×2
HQs:United States×53Australia×2Canada×1China×1Ukraine×1
Who they back
founder profiles across 43 portfolio companiesFounding team size:solo founder×132 founders×153 founders×44+ founders×11
Where their founders studiedfrom 36 founders with education data
Harvard University ×5University of California, Berkeley ×4Harvard Business School ×3Massachusetts Institute of Technology ×3University of Michigan ×3Cornell ×2Dartmouth College ×2McGill University ×2
What their founders studiedfrom 30 founders with field-of-study data
Life Sciences ×15Chemistry ×9Medicine ×5Engineering ×2Physics ×2
Where their founders worked beforefrom 40 founders with career history
Harvard Medical School ×4Receptos ×3Amunix Pharmaceuticals ×2ARCH Venture Partners ×2Atlas Venture ×2Broad Institute of MIT and Harvard ×2Exelixis ×2Exo Therapeutics ×2
20 founders hold a PhD · 4 hold an MBA (of 34 with degree data) · backed the same founder in 2+ companies: 2 founders
Investments · 77 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 12024 · 52023 · 12022 · 22021 · 42020 · 22019 · 12018 · 52017 · 22015 · 531 dated
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Board seatOleg Nodelman· per SEC Form D
Co-investorsAndreessen HorowitzMPM BioImpactMRL Ventures FundPappas CapitalRA CapitalTCG Crossover+5 more
Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease.
BiotechHealthtechMedical DevicesThousand Oaks, US
AnhCo Nguyen(President and Chief Executive Officer)Isaac Ciechanover(Founder)
Co-investorsDag VenturesHEALTHCARE ROYALTY PARTNERSKleiner PerkinsDomain AssociatesFidelity Investments
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Founder)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)
BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)
Co-investorsCardinal PartnersSofinnova VenturesViking GlobalDomain AssociatesDomain PartnersPolaris Partners+2 more
Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions.
BiotechCanton, US
Michael Heffernan(Executive Officer, Director)inPaul Brannelly(Executive Officer)inVikram Karnani(President and Chief Executive Officer, and Director)in
BoardEran Nadav(Director)John Freund(Director)Patrick Heron(Director)in
Co-investorsAPERTURE Venture PartnersFrazier Life SciencesLongitude CapitalBoston Millennia PartnersRA Capital
Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.
BiotechDigital HealthMental HealthCambridge, US
William Huyett(Executive Officer)Mark G. Currie(Executive Officer)inRegina M. Graul(President and Chief Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)
Co-investorsPappas CapitalAberdare VenturesInvusPolaris Partners
Denali Therapeutics develops therapeutics for neurodegenerative diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Marc Tessier-Lavigne(Founder)inAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSteve E. Krognes(Director)inAlexander Schuth(Founder)
Co-investorsARCH Venture PartnersF-Prime CapitalForesite CapitalGV (Google Ventures)Flagship PioneeringFlagship Ventures
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.
BiotechDeep TechMedical DevicesCambridge, US
Feng Zhang(Founder)inGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in
Co-investorsGV (Google Ventures)Sofinnova VenturesViking GlobalAtlas VentureDeerfield Management CompanyFlagship Ventures+2 more
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US
Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsRA CapitalAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management Company+15 more
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)
Co-investorsARCH Venture PartnersBay City CapitalFoothill VenturesNew Enterprise Associates (NEA)Pivotal Life SciencesSamsara BioCapital+3 more
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in
Co-investorsage1Atlas VentureAvoro Capital AdvisorsForesite CapitalOrbiMedRidgeback Capital+1 more
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
PINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inTroy Wilson, Ph.D., J.D.(Co-founder; President, Chief Executive Officer and Chairman of the Board)Kevan M. Shokat, Ph.D.(Founding team member)HEIDI HENSON(Executive Officer)in
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsForesite CapitalNextech InvestOUP (Osage University Partners)
Neurogene develops gene therapy treatments for rare neurological diseases.
BiotechDeep TechDigital HealthLongevityMedical DevicesNew York, US
Rachel McMinn(Founder and Chief Executive Officer)inRachel McMinn, Ph.D.(Founder and Chief Executive Officer)
BoardCory Freedland(Director)inStephen Biggar(Director)
Co-investorsSamsara BioCapitalCasdin CapitalREDMILERTW Investments L.P.William Blair
Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients.
BiotechHealthtechNew York, US
David Hung(Founder)inDavid Hanley(Chief Technical Operations Officer)inGary Hattersley(Chief Scientific Officer)inStacy Markel(Chief People Officer)inPhilippe Sauvage(Chief Financial Officer)inColleen Sjogren(Chief Commercial Officer)in
Co-investorsAisling CapitalDecheng CapitalVertex Ventures ChinaOmega Funds
ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.
BiotechHealthtechSouth San Francisco, US
Richard Heyman(Chairman, Founder, Scientific Advisory Board)inCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Dominic Piscitelli(Chief Financial Officer)inPratik Multani(Chief Medical Officer)inJacob Chacko(President, Chief Executive Officer and Board Member)in
Co-investorsNew Enterprise Associates (NEA)Nextech InvestTaiho Ventures, LLCThe Column GroupViking GlobalOrbiMed
Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.
AI & Machine LearningBiotechDeep TechCambridge, US
Donald A. Bergstrom(Executive Officer)inSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)
Co-investorsCommonweal VenturesForesite CapitalNat TurnerNextech InvestSoftBank Vision FundCurie.Bio+2 more
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)inTimothy Springer(Director)David Hallal(Chief Executive Officer, Chairman and Director)inAkshay Vaishnaw(President of Research & Development and Director)inR. Keith Woods(Chief Operating Officer)inVikas Sinha(Chief Financial Officer)in
Co-investorsAisling CapitalARCH Venture PartnersPolaris PartnersThe Kraft Group
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in
Co-investorsSamsara BioCapitalARCH Venture PartnersPolaris Partners
Shattuck Labs is a biotechnology company developing biologic medicines targeting TNF receptors, including the TL1A/DR3 axis, for patients with cancer and inflammatory or life-altering diseases.
BiotechHealthtechAustin, US
Josiah Hornblower(President/CEO)inTaylor(Co-founder & Chief Executive Officer, Board Member)
BoardWalter Loewenbaum(Director)
Co-investorsHatteras Venture PartnersOrbiMedRocky Point VenturesREDMILET. Rowe Price
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in
BoardDennis Podlesak(Director)inIvor Royston(Director)
Co-investorsAisling CapitalATEM Capital FundAvoro Capital AdvisorsBioBritDelos CapitalForesite Capital+6 more
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)
Co-investorsARCH Venture PartnersGeneral CatalystSamsara BioCapital6 Dimensions CapitalInnovation EndeavorsLeaps by Bayer+6 more
.png)
Epikast provides AI-powered tools for medical science liaisons and field teams to analyze clinical interactions with physicians and patients, and to access synthesized scientific information in their disease areas.
AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBrooklyn, US
Evangelos Vergetis(Executive Officer, Director)
BoardBrad Prosek(Director)Stelios Papadopoulos(Director)Daphne Karydas(Director)Alexandros Tzoukas(Director)
Board seatOleg Nodelman· per SEC Form D
Co-investorsVedanta Capital
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Board seatOleg Nodelman· per SEC Form D
Co-investorsAju IB InvestmentEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)Pfizer Venture Investments+6 more
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)
Board seatOleg Nodelman· per SEC Form D
Co-investorsAtlas VentureAvoro Capital AdvisorsFrazier Life SciencesNextech InvestVida VenturesAbingworth+3 more
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureDroia VenturesGV (Google Ventures)The Column GroupAbbVieJJDC+3 more
Actio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions.
BiotechDeep Tech
David Breckenridge(Founder)inDavid B. Goldstein(Founder)
Co-investorsCanaan PartnersDroia Ventures
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.
AI & Machine LearningBiotechDeep TechWaltham, US
Luc Vandenberghe(Director)Aaron Tward, M.D., Ph.D.(Scientific Co-Founder)Botond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)Rami Daoud(Executive Officer)inRick Modi(Chief Executive Officer, Board Member)
Co-investorsAtlas VentureEight Roads VenturesF-Prime CapitalGV (Google Ventures)New Enterprise Associates (NEA)TCG Crossover
Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.
BiotechMedical DevicesCambridge, US
Richard Malley(Director)inKamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)in
BoardRobert More(Director)Frances Heller(Director)George Siber(Director)
Co-investorsBain Capital Life SciencesForesite CapitalViking GlobalBain CapitalRock Springs CapitalT. Rowe Price
Ajax Systems produces wired and wireless intrusion protection devices for professional security installations, offered through two product lines: Baseline for general projects and Ajax Superior for advanced, high-security applications that require partner accreditation and training.
AI & Machine LearningCybersecurityEnterprise SoftwareHardwareIoT
Aleksandr Konotopskyi(Founder)inOleksandr Konotopskyi(Founder)
Co-investorsEndeavor CatalystHorizon CapitalRevelation Partners
Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery.
AI & Machine LearningBiotechHealthtechNew York, US
Martin Vogelbaum(CEO, co-founder)inRoss Levine(Director)Ramy Farid(Director)
BoardScott Platshon(Director)
Co-investorsInning One VenturesRA CapitalRevelation PartnersVivo Capital
Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.
BiotechHealthtechBrookline, US
Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in
BoardEd Mathers(Director)inKush Parmar(Director)in
Co-investors5AM VenturesNew Enterprise Associates (NEA)Pivotal Life SciencesRA CapitalSofinnova VenturesCowen Healthcare Investments+2 more
Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing retinal disease treatments, specifically engineered biologics for wet AMD, diabetic eye disease, and retinal vein occlusion.
BiotechDigital HealthMedical DevicesBerkeley Heights, US
Napoleone Ferrara(Director & Co-Founder)Srinivas Akkaraju(Director & Co-founder)Mike Dybbs(Director & Co-founder)
A drug discovery company focused on medicinal chemistry and preclinical research across multiple therapeutic areas.
BiotechDigital HealthHealthtechMedical DevicesMental HealthIndianapolis, US
Jaswant Gidda(Executive Officer, Director)inJames Schulz(Executive Officer)Yvonne Lai(Executive Officer)
BoardNora Doherty(Director)Derek Small(Director)Anantha Shekhar(Director)
Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small molecule and monoclonal antibody combination therapies for people with cancer.
BiotechHealthtech
Juan Jaen(Co-founder & President)inTerry Rosen(Co-founder & Chief Executive Officer)inBob Goeltz(Chief Financial Officer)inRichard Markus(Chief Medical Officer)inCarolyn Tang(General Counsel)Yvonne Gehring(SVP, Human Resources)
Co-investorsAisling CapitalDecheng CapitalDroia VenturesForesite CapitalGV (Google Ventures)SLVC+4 more
Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.
BiotechHealthtechMedical DevicesSan Diego, US
Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)Fred Aslan(Executive Officer, Director)inJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)Peter Flynn(Executive Officer)in
Co-investors5AM VenturesRA CapitalvenBio PartnersWellington ManagementvenBio Global Strategic
BiotechRedwood City, US
William Robinson(Director)Lawrence Steinman(Director)Tito Serafini(Executive Officer, Director)
BoardBrian Atwood(Director)Franklin Berger(Director)
Co-investorsAisling CapitalEvolution VC PartnersMission Bay CapitalMission Biocapital
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)inTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)Zaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)
Co-investorsFrazier Life SciencesIllumina VenturesNextech InvestSanofi VenturesVida VenturesGoldman Sachs+1 more
AVTTX is a clinical-stage company developing gene therapy treatments for retinal and ophthalmologic diseases.
BiotechDigital HealthHealthtechMedical Devices
George Montgomery(Executive Chairman)
Co-investorsEvolution VC PartnersHelios CapitalPlum Alley InvestmentsSand Hill AngelsTransform InvestmentsSocii Capital+1 more
BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.
BiotechHealthtech
Neil Kumar(Founder)
Co-investorsAisling CapitalAmzak HealthFrazier Life SciencesHEALTHCARE ROYALTY PARTNERSLongwood FundSequoia Capital+2 more
Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies.
Advanced ManufacturingBiotechMedical DevicesSouth San Francisco, US
Fabian Gerlinghaus(Founder)inOmar Kurdi(Founder)inAlex Pesch(Founder)Fabian Gerlinghaus Omar Kurdi(Founder)
BoardJustin Butler(Director)inVictor Tong(Director)in
Co-investorsDecheng Capital8VCIntuitive VenturesKoch Disruptive TechnologiesBaillie GiffordBlackRock+4 more
Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.
BiotechHealthtech
Co-investorsAdvent Life SciencesForesite CapitalLifeSci Venture PartnersMedicxiOberland CapitalScion Life Sciences+4 more
Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.
BiotechSeattle, US
Doug Williams(Executive Officer, Director)in
BoardNoubar Afeyan(Director)inSteven Gillis(Director)Eric Lander(Director)
Co-investorsARCH Venture PartnersAlexandriaFidelity InvestmentsFlagship PioneeringQatar Investment Authority
Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.
CleantechClimate TechDeep TechNew Materials
Chiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in
Co-investorsImpact Ventures Management Pty LtdPacific Channel3E Bioventures CapitalARCH Venture PartnersGeneral CatalystLeaps by Bayer+3 more
Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.
AI & Machine LearningBiotechHealthtechWatertown, US
Alex Lugovskoy(Founder)Michael Gladstone(Founder)
Co-investorsAtlas VentureFrazier Life SciencesRA CapitalRV Invest GmbHSanofi VenturesViking Global
Pioneering a drug discovery method based on tracking the movement of individual proteins in living cells.
Eric Betzig(Founder)Luke Lavis(Founder)Robert Tjian(Founder)Xavier Darzacq(Founder)
Co-investorsHorizons VenturesLux CapitalTCG CrossoverThe Column GroupWPSS InvestmentsGeneral Catalyst+1 more
ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.
BiotechDeep TechHealthtechWaltham, US
David Hallal(CEO)inMike Paglia(Chief Technology Officer)Ger Brophy(CEO)in
Co-investorsMPM BioImpactSamsara BioCapitalSoftBank Vision Fund
Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives.
BiotechDigital HealthHealthtechMedical Devices
Dr. Rod MacKinnon(Founder)
Co-investorsBessemer Venture PartnersLightstone VenturesLongwood Fund
Kezar Life Sciences is a clinical-stage biotechnology company developing small-molecule therapeutics for immune-mediated diseases and cancer.
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)
BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)
Co-investorsBay City CapitalChiesi VenturesPappas CapitalQiming Venture Partners USASolasta VenturesCowen Healthcare Investments+1 more
Kronos Bio was a clinical-stage biopharmaceutical company developing small molecule therapeutics that target deregulated transcription factor networks implicated in cancer.
BiotechNew York, US
Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)
BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)
Co-investorsGV (Google Ventures)Nextech InvestVida VenturesBlackRockCommodore CapitalInvus+2 more
Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.
BiotechSan Diego, US
Yi Liu(Executive Officer, Director)inYi Liu, Ph.D.(CEO)Lynn Yang(Director)
BoardCarl Gordon(Director)in
Co-investorsOrbiMedRoche Venture Fund
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Co-investorsage1LAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)Vivo Capital+8 more
HealthtechWest Lafayette, US
Philip Low, Ph.D.(Director)Sunil Singhal, M.D.(Director)Isaac Barchas(Director)Clay B. Siegall, Ph.D.(Executive Officer, Director)Ronald Martell(Director)inFranklyn Prendergast, M.D., Ph.D.(Director)
Co-investorsArsenal Bridge VentureJanus Henderson InvestorsREDMILE
BiotechDublin 1
Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)
Co-investorsAisling CapitalFrazier Life SciencesLongitude CapitalMESA VERDE VENTURE PARTNERSNovartis Venture Fund
Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.
BiotechEvanston, US
Joseph R. Moskal(Executive Officer)inAmin Khan(Executive Officer)inJames Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)
Co-investorsCota CapitalLatterell Venture PartnersSofinnova VenturesAdams Street Partners
Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.
BiotechNew York, US
Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)
BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)
Co-investorsJeito CapitalVida VenturesTPG
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.
BiotechHealthtechWilmington, CN
Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)
BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)
Co-investorsHBM Healthcare InvestmentsHBM PartnersLAVLilly Asia VenturesRA CapitalSamsara BioCapital+3 more
Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US
Arthur T. Sands(Executive Officer, Director)inGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)
BoardDavid Goeddel(Director)inMark Goldsmith(Director)
Co-investorsBain Capital Life SciencesForesite CapitalSofinnova VenturesThe Column GroupWellington ManagementThird Rock Ventures
Omniox is an IND-stage biotherapeutics company developing its H-NOX platform into OMX oxygen delivery biologics that carry oxygen to hypoxic tissues where low oxygen levels drive disease.
BiotechMedical DevicesSan Francisco, US
Jonathan Winger(Executive Officer, Director)inStephen Cary(Executive Officer, Director)
BoardJeffrey S. Samberg(Director)Laurence Marton(Director)Mitchell Mutz(Director)John Wesley(Director)
Co-investorsWavemaker Three-Sixty Health
Paratus Sciences is a drug discovery company that uses AI-powered methods to identify first-in-class medicines by studying evolutionary traits, targeting serious diseases where current therapies are inadequate.
AI & Machine LearningBiotechDeep TechUnited States, US
Co-investorsARCH Venture PartnersClavystBioLeaps by Bayer
BiotechMenlo Park, US
Ervin Epstein(Executive Officer, Director)inJean Tang(Director)Mark de Souza(Executive Officer)
BoardKatrin Andreasson(Director)
Co-investorsAisling Capital
RubiusTX provides independent reviews and research on Australian online casinos, focusing on licensing, player protections, payouts, and responsible gambling standards.
ConsumerGaming
BiotechMedical Devices
Co-investorsARCH Venture Partners
BiotechDigital HealthMedical DevicesSeattle, US
Peter A. Thompson(Executive Officer, Director)in
Co-investorsPontifax Venture CapitalRA CapitalUS Venture PartnersAlexandriaNextech InvestOrbiMed
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)inPeter McNamara(Executive Officer)in
Co-investorsVida VenturesAlly Bridge GroupClarus VenturesPolaris PartnersSoleus Capital
Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry.
BiotechDeep TechSouth San Francisco, US
Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)in
BoardMichael Goller(Director)Reid Huber(Director)inPeter Thompson(Director)in
Co-investorsOrbiMedRA CapitalNovo HoldingsThird Rock Ventures
Unity Biotechnology was a biotechnology company that is no longer operating.
BiotechBrisbane, US
Nathaniel E. David(Executive Officer, Director)inDan Marquess(Executive Officer)inKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in
Co-investorsage1Alumni VenturesARCH Venture PartnersCycad Group LLCKhosla VenturesVenrock+6 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AmagmatxAviditynanoClementiapharmaKindredbioMagenta TherapeuticsNotchtxPrevail TherapeuticsPrevailtherapeuticsvisit www.morphictx.comZappRx
Exits · 26
21 IPOs · 5 acquisitions · showing 21Aktis OncologyNASDAQ: AKTSAtara BiotherapeuticsNASDAQ: ATRAaTYR PHARMANASDAQ: ATYRCollegium PharmaceuticalNASDAQ: COLLCyclerion TherapeuticsNASDAQ: CYCNDenali TherapeuticsNASDAQ: DNLIEditas MedicineNASDAQ: EDITFreenomeNASDAQ: FRNMGossamer BioNASDAQ: GOSSIntellia TherapeuticsNASDAQ: NTLAKura OncologyNASDAQ: KURANeurogeneNASDAQ: NGNENuvation BioNYSE: NUVBORIC PharmaceuticalsNASDAQ: ORICRelayNASDAQ: RLAYScholar RockNASDAQ: SRRKScholar Rock Holding Corp, Inc.NASDAQ: SRRKShattuck LabsNASDAQ: STTKSyndax PharmaceuticalsNASDAQ: SNDXSagerxacq. by Supernus PharmaceuticalsSilverback Therapeuticsacq. by ARS Pharmaceuticals
Portfolio news
latest coverage across their companiesNeurogene · stocktitan.net · Sep 8, 2026
Cellares · finsmes.com · Jun 15, 2026
Terremotobio · finsmes.com · Apr 15, 2026
Affinia Therapeutics · finsmes.com · Oct 8, 2025
IPO stake values · per SEC filings · 5
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| ORIC Pharmaceuticals | 7.4% | $23.00 | Nov 2020 | $60.8M |
| Aktis Oncology | 5.0% | $18.00 | Jan 2026 | $46.8M |
| Scholar Rock | 4.1% | $14.00 | May 2018 | $13.9M |
| Scholar Rock Holding Corp, Inc. | 4.1% | $14.00 | May 2018 | $13.9M |
| Kura Oncology | 10.0% | $8.00 | Nov 2015 | $11.6M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Jun 2023
Disclosed stake · filed Mar 2021
Disclosed stake · filed Mar 2021
Disclosed stake · filed Mar 2021
Disclosed stake · filed Feb 2021
Disclosed stake · filed Jun 2016
35 insider ownership filings (Forms 3/4/5)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has EcoR1 Capital made?
- EcoR1 Capital has 77 tracked investments, 26 of which have exited, including 4 dated in the last 24 months.
- What stage does EcoR1 Capital invest at?
- EcoR1 Capital invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does EcoR1 Capital focus on?
- EcoR1 Capital focuses on Biotech, Medical Devices.
- Where is EcoR1 Capital located?
- EcoR1 Capital is headquartered in San Francisco, US.
- Who does EcoR1 Capital co-invest with?
- EcoR1 Capital most often shares deals with RA Capital, ARCH Venture Partners, Foresite Capital, among 118 tracked co-investors.
Images
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.